Dear Editor,

I read with great interest the article entitled “18F-FMISO PET/CT detects hypoxic lesions of cardiac and extracardiac involvement in patients with sarcoidosis”. FMISO is a promising radiotracer because as shown by Furuya et al.1 it has no physiological myocardial uptake and did not require special preparation (low carbohydrate diet at least 24 hours before performing the exam, the fasting state of patient and the difficult glycemic control in diabetic patients). Although the small sample size of the dataset of patients, I think that this tracer could be the future in the diagnostic setting of cardiac sarcoidosis and his extracardiac involvement sites. Further studies also in multicenter controlled trials are needed to confirm this promising results.